The maker of SuperPretzel and ICEE brands reported quarterly sales of $343.8 million, falling short of Wall Street forecasts and marking a year-over-year decline. Adjusted earnings also missed analyst expectations.
As artificial intelligence transforms every sector, CEOs are under unprecedented pressure to demonstrate fluency and generate returns. This new mandate is shortening tenures, favoring a younger, more adaptable generation of leaders, and redefining the very skills required to steer a modern enterprise.
A growing number of incidents where hotels and gas stations refuse service to federal immigration officers has ignited a fierce national debate, pitting private business rights against accusations of discrimination and raising complex legal questions.
U.S. Attorney for D.C. Jeanine Pirro faces backlash after stating she would jail anyone bringing a firearm into the District, regardless of permits from other jurisdictions, igniting a debate over gun rights and federal enforcement.
CNBC's Jim Cramer includes Pfizer in his weekly game plan but voices unease over the pharmaceutical giant's pipeline, questioning where its next blockbuster drug will come from despite an attractive dividend yield.
CNBC's Jim Cramer has spotlighted Merck & Co. as a strategic holding, praising the pharmaceutical giant's acquisition-driven strategy to build a more balanced portfolio ahead of its blockbuster drug's patent cliff.
While the average retiree receives just under $2,000 monthly, those in the highest income brackets can secure nearly $3,000. We break down the numbers for affluent retirees in their 80s and what it means for retirement security.
Many retirees face unexpected healthcare costs, and late enrollment in Medicare can lead to lifelong surcharges. Here’s a guide to timing your sign-up and avoiding unnecessary penalties.
A coalition of activist groups, emboldened by Health Secretary Robert F. Kennedy Jr.'s influence and a landmark law in Idaho, is launching a coordinated campaign to challenge or repeal vaccine requirements in multiple states this year, raising public health concerns.
Merck & Co. projected 2026 revenue below Wall Street expectations, citing a steeper-than-anticipated impact from patent expirations on key drugs like Januvia. The forecast overshadowed a strong Q4 performance driven by its blockbuster cancer therapy, Keytruda.
As major indices rally, savvy investors are turning to overlooked small-cap stocks where recent insider buying hints at underlying value and confidence. We examine three such companies across banking and consumer goods, dissecting their financials and strategic moves in a buoyant market.
The German industrial giant plans to expand manufacturing across five states and open a new Mississippi facility, targeting gas turbine and grid tech production while creating 1,500 jobs, as electricity demand from data centers reshapes the American energy landscape.
With institutional shareholders dominating ownership, Kearny Financial Corp.'s stock trajectory is closely tied to the moves of major funds. While this brings credibility, it also introduces volatility risks that retail investors should watch.
As Bob Iger prepares to pass the CEO baton, his successor inherits a media empire at a crossroads. While theme parks thrive, the new leader must navigate streaming wars, a declining linear TV business, industry consolidation, and the unpredictable impact of AI on creativity.
JPMorgan Chase & Co. reported stronger-than-expected fourth-quarter earnings, driven by lower expenses and credit provisions. However, a miss in investment banking revenue triggered a sell-off, highlighting investor focus on future growth drivers amid a mixed economic outlook.
Despite the nomination of a Fed chair seen as more dovish, structural factors and market complexities mean prospective homebuyers should not expect a dramatic drop in borrowing costs this year.
RBC Capital has trimmed its price target for EOG Resources, citing a more conservative long-term view on oil prices. The adjustment reflects lowered 2026 WTI forecasts and impacts the shale producer's earnings and cash flow projections.
Analysts at Leerink Partners have raised their price target for Bristol-Myers Squibb (BMY), highlighting a series of pivotal clinical trial results expected in 2025. The firm sees significant upside potential as the market currently undervalues the company's robust pipeline, despite near-term earnings adjustments.
Raymond James Financial reported a 6% year-over-year revenue increase to $3.7 billion for its fiscal first quarter, though net income declined, highlighting a mixed performance as its wealth management arm showed strength.
Trulieve Cannabis Corp. has secured an additional $60 million in senior secured notes, bringing its total debt issuance to $200 million. The move comes as the multi-state operator's stock shows significant long-term gains despite recent volatility, raising questions about its valuation amid a complex regulatory landscape.
